Loading…
for educational and safety purposes
Selegiline and BPAP both come up in the same conversations; they overlap on Dopamine. Selegiline: Selegiline, also known as L-deprenyl, is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B), used in the treatment of Parkinson's disease and, in a transdermal patch form, of major depressive disorder. BPAP: BPAP is an experimental laboratory compound created in the late 1990s by the Hungarian and Japanese team behind selegiline; it has never been approved as a medicine in any country.
Selegiline, also known as L-deprenyl, is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B), used in the treatment of Parkinson's disease and, in a transdermal patch form, of major depressive disorder. At low doses it selectively spares MAO-A, which avoids the dietary tyramine restrictions required by older monoamine oxidase inhibitors, though this selectivity is lost at higher doses. It is marketed under names including Eldepryl, Zelapar, and, as a skin patch, Emsam.
BPAP is an experimental laboratory compound created in the late 1990s by the Hungarian and Japanese team behind selegiline; it has never been approved as a medicine in any country. It is described as a "monoaminergic activity enhancer", meaning that in animal tissue it makes dopamine, noradrenaline and serotonin neurons release more transmitter when they fire, rather than forcing transmitter out the way amphetamine does; at higher concentrations it also blocks dopamine and noradrenaline reuptake. Essentially all the evidence comes from rats, mice and cell cultures, and almost all of it was produced by the two groups with a stake in the compound, namely Knoll's Semmelweis University laboratory and Fujimoto Pharmaceutical Corporation. No clinical trial in humans has ever been run or even registered, so claims about memory, mood, longevity or anti-aging benefit in people rest on no human evidence at all.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
irreversible inhibitor
inhibits
protects neurons
enhances (not releases)
Uptake inhibitor
NOT an inhibitor (explicit negative)
Uptake inhibitor
Weak uptake inhibitor
Weak ligand; neuroprotection blocked by sigma antagonist BD1063
agonist
Proposed agonist
Proposed interaction at a distinct site; enhances vesicular monoamine accumulation and release
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Selegiline is currently listed by more trusted vendors (2), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.